Modified transarterial chemoembolization with locoregional administration of sorafenib for treating hepatocellular carcinoma

TY - JOUR

T1 - Modified transarterial chemoembolization with locoregional administration of sorafenib for treating hepatocellular carcinoma

T2 - feasibility, efficacy, and safety in the VX-2 rabbit liver tumor model

AU - Seidensticker, Max

AU - Streit, Sebastian

AU - Nass, Norbert

AU - Wybranski, Christian

AU - Jürgens, Julian

AU - Brauner, Jan

AU - Schulz, Nadine

AU - Kalinski, Thomas

AU - Seidensticker, Ricarda

AU - Garlipp, Benjamin

AU - Steffen, Ingo

AU - Ricke, Jens

AU - Dudeck, Oliver

PY - 2016/6/23

Y1 - 2016/6/23

N2 - PURPOSE: We aimed to assess the feasibility, efficacy and safety of a local application of sorafenib within a conventional transarterial chemoembolization in the VX-2 tumor-bearing rabbit model.METHODS: VX-2 tumors were induced in the left liver lobe of 10 New Zealand White rabbits. After two weeks, growth was verified by contrast-enhanced computed tomography (CT). Five rabbits were treated by transarterial chemoembolization using an emulsion of sorafenib and ethiodized oil (referred to as SORATACE; n=5). Rabbits receiving oral sorafenib for two weeks (n=2) and untreated rabbits (n=3) served as controls. After two weeks, contrast-enhanced CT was performed, followed by animal necropsy.RESULTS: The change in tumor diameter between baseline and follow-up was significantly different in the SORATACE group compared with the other groups; tumor shrinkage was observed in the SORATACE group only (P = 0.016). In both control groups, preserved hypervascularity was seen in the follow-up CT in all but one tumor. All tumors in the SORATACE group were devascularized in the follow-up CT. Importantly, substantial parenchymal damage in nontargeted areas of the tumor-bearing liver lobe was seen in rabbits treated with SORATACE.CONCLUSION: SORATACE demonstrated high efficacy in the treatment of experimental VX-2 liver tumors but was also associated with substantial liver parenchymal toxicity.

AB - PURPOSE: We aimed to assess the feasibility, efficacy and safety of a local application of sorafenib within a conventional transarterial chemoembolization in the VX-2 tumor-bearing rabbit model.METHODS: VX-2 tumors were induced in the left liver lobe of 10 New Zealand White rabbits. After two weeks, growth was verified by contrast-enhanced computed tomography (CT). Five rabbits were treated by transarterial chemoembolization using an emulsion of sorafenib and ethiodized oil (referred to as SORATACE; n=5). Rabbits receiving oral sorafenib for two weeks (n=2) and untreated rabbits (n=3) served as controls. After two weeks, contrast-enhanced CT was performed, followed by animal necropsy.RESULTS: The change in tumor diameter between baseline and follow-up was significantly different in the SORATACE group compared with the other groups; tumor shrinkage was observed in the SORATACE group only (P = 0.016). In both control groups, preserved hypervascularity was seen in the follow-up CT in all but one tumor. All tumors in the SORATACE group were devascularized in the follow-up CT. Importantly, substantial parenchymal damage in nontargeted areas of the tumor-bearing liver lobe was seen in rabbits treated with SORATACE.CONCLUSION: SORATACE demonstrated high efficacy in the treatment of experimental VX-2 liver tumors but was also associated with substantial liver parenchymal toxicity.

KW - Animals

KW - Carcinoma, Hepatocellular

KW - Cell Line, Tumor

KW - Chemoembolization, Therapeutic

KW - Drug Administration Schedule

KW - Female

KW - Liver Neoplasms

KW - Neoplasm Transplantation

KW - Niacinamide

KW - Phenylurea Compounds

KW - Rabbits

KW - Tomography, X-Ray Computed

KW - Treatment Outcome

KW - Tumor Burden

KW - Journal Article

U2 - 10.5152/dir.2016.15462

DO - 10.5152/dir.2016.15462

M3 - SCORING: Journal article

C2 - 27328720

VL - 22

SP - 378

EP - 384

JO - DIAGN INTERV RADIOL

JF - DIAGN INTERV RADIOL

SN - 1305-3825

IS - 4

ER -